Pediatric Allogeneic Bone Marrow Transplantation at Motol University Hospital, Prague, Czechia

Motol University Hospital in Prague serves as the flagship of central European medicine, offering a premier allogeneic bone marrow transplantation program that bridges the gap between sophisticated pediatric care and adult hematology. As one of the largest medical complexes in Europe, Motol is uniquely positioned to offer lifespan care, utilizing its dual-section structure to provide specialized transplant protocols for both children and adults. The bone marrow transplant unit is a high-tech facility characterized by a massive infrastructure of HEPA-filtered sterile rooms and an integrated laboratory network for real-time flow cytometry and PCR diagnostics. By operating under the strict oversight of the Czech Ministry of Health and maintaining prestigious SAK and JACIE-standard certifications, Motol provides a clinical environment where safety and innovation are paramount. Patients benefit from a deeply collaborative medical ecosystem in which transplant surgeons, hematologists, and clinical pharmacists work together to navigate the complexities of allogeneic grafting from both related and unrelated donors. The scope of the allogeneic program at Motol encompasses a diverse array of life-threatening hematological and genetic conditions, providing a definitive therapeutic option where conventional treatments may fail. The clinical team specializes in treating high-risk malignancies such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML), particularly in cases of relapse or poor molecular response. Beyond the oncology sector, Motol is a central hub for treating severe non-malignant disorders, including primary immunodeficiencies, severe aplastic anemia, and inherited metabolic diseases. The hospital is notably recognized for its work with rare congenital disorders of hemoglobin formation, such as alpha and beta thalassemia, where successful allogeneic transplantation can effectively "reset" the patient’s hematopoietic system. Each treatment plan is informed by the extensive DNA and electrophysiology labs, ensuring that the transplant approach is precisely matched to the patient's specific genetic and cytogenetic markers. The institutional experience at Motol University Hospital is vast, with a legacy of transplant excellence dating back to the program's inception in the mid-1980s. In the Children's Section alone, which is regarded as the top pediatric facility in Central Europe, the hospital performs approximately 20 to 35 allogeneic transplants annually. When combined with the adult department, the hospital contributes significantly to the national total of several hundred transplants performed across the Czech Republic's major centers. For example, recent institutional reports from specific years highlight active periods during which over 33 pediatric allogeneic transplants were performed, with the vast majority (approximately 85%) utilizing matched unrelated donors sourced from international registries. This high volume of cases has allowed the Motol team to refine their techniques in haploidentical (half-matched) and sibling donor transplants, ensuring a viable graft source for nearly every patient in need. Furthermore, Motol’s transplant program is distinguished by its focus on long-term quality of life; the hospital operates specialized outpatient units for late consequences, ensuring that survivors of allogeneic transplants receive ongoing monitoring for years after their initial procedure. This commitment to long-term success, backed by thousands of successfully treated patients over four decades, positions Motol as a global leader in cellular therapy.